ValuEngine Lowers Teva Pharmaceutical Industries (NYSE:TEVA) to Buy

Share on StockTwits

ValuEngine downgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday, ValuEngine reports.

Several other research analysts have also recently issued reports on the stock. Royal Bank of Canada reiterated a hold rating and set a $10.00 target price on shares of Teva Pharmaceutical Industries in a report on Thursday, August 8th. Cowen set a $9.00 target price on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Wednesday, August 7th. UBS Group set a $8.00 price target on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a report on Friday, August 16th. BMO Capital Markets lowered their price target on shares of Teva Pharmaceutical Industries from $11.00 to $9.00 and set a market perform rating for the company in a research report on Friday, August 9th. Finally, Wells Fargo & Co lowered their price target on shares of Teva Pharmaceutical Industries from $17.00 to $8.00 and set a market perform rating for the company in a research report on Monday, September 30th. Five investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $10.64.

Shares of TEVA stock traded up $0.09 during mid-day trading on Tuesday, hitting $9.92. The stock had a trading volume of 11,074,047 shares, compared to its average volume of 17,221,416. Teva Pharmaceutical Industries has a 12-month low of $6.07 and a 12-month high of $20.34. The firm has a market capitalization of $10.93 billion, a P/E ratio of 3.54, a price-to-earnings-growth ratio of 1.12 and a beta of 1.82. The firm’s 50-day moving average is $9.16 and its two-hundred day moving average is $8.35. The company has a debt-to-equity ratio of 1.62, a current ratio of 0.89 and a quick ratio of 0.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.56 EPS for the quarter, missing the consensus estimate of $0.58 by ($0.02). The firm had revenue of $4.26 billion for the quarter, compared to analysts’ expectations of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. Analysts expect that Teva Pharmaceutical Industries will post 2.26 EPS for the current year.

In other news, VP Hafrun Fridriksdottir sold 4,310 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.49, for a total value of $45,211.90. Following the sale, the vice president now directly owns 24,883 shares in the company, valued at approximately $261,022.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 18,033 shares of company stock worth $102,261 over the last 90 days. Company insiders own 0.49% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. NEXT Financial Group Inc boosted its position in shares of Teva Pharmaceutical Industries by 384.8% in the 2nd quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock worth $39,000 after purchasing an additional 3,394 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in Teva Pharmaceutical Industries by 14.7% in the second quarter. Daiwa Securities Group Inc. now owns 40,583 shares of the company’s stock worth $375,000 after acquiring an additional 5,200 shares in the last quarter. Hartford Investment Management Co. grew its stake in shares of Teva Pharmaceutical Industries by 6.6% during the second quarter. Hartford Investment Management Co. now owns 28,324 shares of the company’s stock worth $261,000 after acquiring an additional 1,748 shares during the last quarter. Strs Ohio grew its stake in shares of Teva Pharmaceutical Industries by 1,909.4% during the second quarter. Strs Ohio now owns 1,651,700 shares of the company’s stock worth $15,245,000 after acquiring an additional 1,569,500 shares during the last quarter. Finally, PGGM Investments grew its stake in shares of Teva Pharmaceutical Industries by 6.3% during the second quarter. PGGM Investments now owns 1,613,034 shares of the company’s stock worth $14,888,000 after acquiring an additional 95,000 shares during the last quarter. 54.10% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Further Reading: What is net income?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.